

# Performance of a new needle system for lumbar punctures in children with blood cancer (leukemia)

<b>Submission date</b> 28/06/2022	<b>Recruitment status</b> Stopped	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 08/07/2022	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/04/2024	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Acute lymphoblastic leukemia is the most common type of blood cancer diagnosed in children. At present, the mean long-term survival from this disease is well over 90%. However, the patient's prognosis weakens if the lumbar puncture causes blood leakage into the spinal canal and blast cells enter the cerebrospinal fluid. There is considerable blood leakage in one out of five lumbar punctures in pediatric patients with leukemia on average. In other words, the procedure is considered traumatic.

A new bioimpedance needle system was recently found feasible in lumbar punctures of pediatric patients with leukemia. The device measures electrical resistance at the needle tip and detects when the needle tip reaches the spinal canal. With this device, lumbar punctures were successful at the first attempt in 80% of performed procedures and only one out of ten lumbar punctures was traumatic. The present study compares the performance of the new device with the conventional spinal needle in clinical practice.

### Who can participate?

All children with leukemia, whose diagnosis or therapy requires lumbar punctures and who are willing to participate in the study

### What does the study involve?

The method used in the patient's first study lumbar puncture is randomly allocated. Thereafter, either a bioimpedance needle system or a conventional spinal needle are alternately used. The maximum number of study procedures per patient is limited to four.

### What are the possible benefits and risk of participating?

In the long term, a lower incidence of traumatic lumbar puncture may translate into patients' improved prognosis and event-free survival. The study is conducted within the usual clinical workflow of pediatric hemato-oncology clinics. Thus, taking part in the study does not require any extra effort from the participant and there are no additional risks of harm or injury.

Where is the study run from?  
Tampere University Hospital (Finland)

When is the study starting and how long is it expected to run for?  
January 2022 to August 2024

Who is funding the study?  
Investigator-initiated and funded

Who is the main contact?  
1. Dr Sauli Palmu (Finland)  
sauli.palmu@tuni.fi  
2. Dr Harri Sievänen (Finland)  
harri.sievanen@injeq.com

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Harri Sievänen

**ORCID ID**  
<http://orcid.org/0000-0003-3172-248X>

**Contact details**  
Injeq Oy  
Biokatu 8  
Tampere  
Finland  
33520  
+358 (0) 509 100 969  
harri.sievanen@injeq.com

**Type(s)**  
Principal Investigator

**Contact name**  
Dr Sauli Palmu

**ORCID ID**  
<http://orcid.org/0000-0003-3270-7660>

**Contact details**  
Tampere Center for Child  
Adolescent and Maternal Health Research  
Tampere University Hospital  
PO Box 2000  
Tampere  
Finland

33521  
+358 (0) 3311611  
sauli.palmu@tuni.fi

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**

**ClinicalTrials.gov number**  
Nil known

**Secondary identifying numbers**  
IQ-LP-04

## Study information

**Scientific Title**  
Success and complications in lumbar punctures of pediatric patients with leukemia: A randomized clinical crossover trial of a bioimpedance needle system versus conventional procedure

**Study objectives**  
The performance of the bioimpedance needle system (IQ-Tip system) is at least comparable to the conventional spinal needle regarding the incidence of traumatic lumbar punctures in pediatric hemato-oncology patients

**Ethics approval required**  
Old ethics approval format

**Ethics approval(s)**  
Approved 10/05/2022, Regional Ethics Committee of the Expert Responsibility Area of Tampere University Hospital (TAYS Research Services, PO Box 2000, 33521, Tampere, Finland; +358 50 3295 667; eettinen@pshp.fi), ref: R22039L

**Study design**  
Multicenter randomized crossover noninferiority trial

**Primary study design**  
Interventional

**Secondary study design**  
Randomised cross over trial

**Study setting(s)**  
Hospital

**Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Diagnostics and intrathecal treatment of pediatric patients with leukemia

### **Interventions**

Patients' lumbar puncture procedures are alternately performed either with the IQ-Tip system (study arm A) or the conventional spinal needle (study arm B). The maximum number of procedures per patient is four and the method of the first procedure is randomly assigned yielding two possible sequences (either ABAB or BABA)

### **Intervention Type**

Device

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

-

### **Primary outcome measure**

Incidence of traumatic lumbar puncture measured as the proportion of traumatic lumbar punctures (threshold  $\geq 10$  erythrocytes/ $\mu$ l in a cerebrospinal fluid sample) out of all lumbar puncture procedures performed in the given arm after the data collection of the study is completed

### **Secondary outcome measures**

1. First puncture success rate measured as the proportion of successful lumbar puncture procedures at the first attempt (one skin penetration) out of all lumbar puncture procedures performed in the given arm after the data collection of the study is completed
2. Incidence of post-dural puncture headache (PDPH) measured as the proportion of lumbar puncture procedures with subsequent PDPH out of all lumbar puncture procedures performed in the given arm after the data collection of the study is completed

### **Overall study start date**

14/01/2022

### **Completion date**

31/08/2024

### **Reason abandoned (if study stopped)**

Lack of funding/sponsorship

## **Eligibility**

### **Key inclusion criteria**

1. Aged between 1 and 18 years old at the beginning of the study
2. Diagnosis or treatment plan requires multiple lumbar puncture procedures for collecting cerebrospinal fluid samples and injecting intrathecal therapy
3. Planned lumbar puncture procedures will be performed with 22G Quincke-type spinal needles
4. At least two lumbar puncture procedures left in the patient's treatment protocol
5. Both the parent(s) and the patient, depending on the patient's age, give a signed informed consent before the first study lumbar puncture procedure

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

1 Years

**Upper age limit**

18 Years

**Sex**

Both

**Target number of participants**

75

**Key exclusion criteria**

1. Parent(s) and/or the patient refuse to participate in the trial
2. Parent(s) and/or the patient are considered unable to give informed consent
3. Temporary contraindication to performing a lumbar puncture procedure

**Date of first enrolment**

11/05/2023

**Date of final enrolment**

31/07/2024

**Locations****Countries of recruitment**

Finland

**Study participating centre**

**Tampere University and Tampere University Hospital**

Tampere Center for Child, Adolescent and Maternal Health Research

Faculty of Medicine and Health Technology

Teiskontie 35

Tampere  
Finland  
33520

**Study participating centre**  
**New Children's Hospital**  
Helsinki University Hospital  
Department of Pediatric Hematology  
Oncology and Stem Cell Transplantation  
Stenbäckinkatu 9  
Helsinki  
Finland  
00290

**Study participating centre**  
**Turku University Hospital**  
Department of Pediatric and Adolescent Hematology and Oncology  
Savitehtaankatu 5  
Turku  
Finland  
20520

**Study participating centre**  
**Oulu University Hospital**  
Department of Pediatric Hematology and Oncology  
Kajaanintie 50  
Oulu  
Finland  
90220

**Study participating centre**  
**Kuopio University Hospital**  
Department of Pediatric Hematology and Oncology  
Puijonlaaksontie 2  
Kuopio  
Finland  
70210

**Sponsor information**

## Organisation

Injeq Plc

## Sponsor details

Biokatu 8

Tampere

Finland

33520

+358 (0) 405 805 944

info@injeq.com

## Sponsor type

Industry

## Website

<https://www.injeq.com>

# Funder(s)

## Funder type

Other

## Funder Name

Investigator initiated and funded

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal in the field of hemato-oncology

## Intention to publish date

31/12/2024

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to reasons pertaining to ethics and data protection of health data of a relatively rare disease

## IPD sharing plan summary

Not expected to be made available

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		21/07/2023	21/07/2023	Yes	No